Director's Dealing • Nov 24, 2025
Director's Dealing
Open in ViewerOpens in native device viewer
| 1 | Details of the person discharging managerial responsibilities | ||
|---|---|---|---|
| a) | Name | Michael Engsig | |
| b) | Position | Chief Executive Officer | |
| 2 | Reason for notification | ||
| a) | Initial notification/ Amendment |
Initial | |
| 3 | Details of issuer | ||
| a) | Name | Nykode Therapeutics ASA | |
| b) | LEI | 254900UKQHWYZJD22017 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
| a) | Description of the financial instrument, type of instrument |
Shares in Nykode Therapeutics ASA (ISIN: NO0010714785) | |
| b) | Nature of the transaction |
Acquisition of shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| NOK 2.16 | 46,356 | ||
| d) | Aggregated information | Price | NOK 2.16 |
| -Average price, | Volume | 46,356 | |
| aggregated volume and total amount |
Total amount | NOK 100,128.96 | |
| e) | Date of the transaction | 24.11.2025 | |
| f) | Place of the transaction | XOSL - Oslo Stock Exchange |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.